Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Post by Trippedstockson Feb 13, 2021 11:10am
328 Views
Post# 32561603

UCSF - Medical Center

UCSF - Medical Center
Dr. Fahy began working with RVV on Dec. 31, 2020. San Francisco had over 200 Hospitalized cases of Covid-19. Two weeks later there was about 160. On Jan 29 there was 122. At that same time there was about 50 cases in ICU with the larger ICU being at UCSF. On Jan 29. 20 in ICU at UCSF medical center. As well there would be 30 additional hospitalized patients at UCSF. Who is in charge of patient care in ICU at UCSF and would have significant influence (in the bay area) in standard care of hospitalized Covid-19 patients, not just at UCSF?

q "Dr. John Fahy, MD, MSc is a Professor of Medicine in the Division of Pulmonary and Critical Care Medicine and the Department of Medicine at the University of California San Francisco and is a director of UCSFs severe asthma clinic. He also cares for critically ill patients in the intensive care units and directs the UCSF Airway Clinical Research Center."

Now with his known thiol research, he would most likely be willing to give a thiol drug to a patient. What drug and company have a IND EAP for a thiol drug? Dr. Fahy isn't just reviewing the clinical results, he IS the EAP.

Am I connecting dots?

https://www.latimes.com/projects/california-coronavirus-cases-tracking-outbreak/san-francisco-county/
<< Previous
Bullboard Posts
Next >>